Christie P M Verkleij

6PUBLICATIONS
20CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Christie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans

|Mar 06, 2023
Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.

Anne W J Martens, Joanne M Rietveld, Renate de Boer

|Oct 13, 2021
Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Mashhour Hosny, Christie P M Verkleij, Jort van der Schans

|Oct 09, 2021
Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.

Kristine A Frerichs, Monique C Minnema, Mark-David Levin

|Jun 02, 2021
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients.

Kristine A Frerichs, Christie P M Verkleij, Meletios A Dimopoulos

|Dec 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.

Christie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans

Pageof 1

Frequent Collaborators

5 joint publications

Niels W C J van de Donk

2 joint publications

Sonja Zweegman

2 joint publications

Raluca Verona

1 joint publications

Meletios A Dimopoulos